X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The collaboration aims to bolster access to healthcare by expanding the availability of Tiotropium Bromide Inhalation Powder, to COPD patients in the US.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Spiriva HandiHaler-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mark Cuban Cost Plus Drug Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2023
Details:
Tiotropium bromide Inhalation powder for capsule, a generic equivalent of Spiriva HandiHaler, inhibits M3-receptors, that is indicated for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Spiriva HandiHaler-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Tiotropium bromide inhalation powder exhibits pharmacological effects through inhibition of M3-receptors and used for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Spiriva-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
Spiriva Handihaler (tiotropium bromide), an inhalation powder, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease and asthma.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Spiriva Handihaler-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
Spiriva-Generic (tiotropium bromide) inhalation powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Spiriva-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is a prescription medicine used long term, 2 puffs 1 time each day, in controlling symptoms in adults with chronic obstructive pulmonary disease (COPD).
Lead Product(s): Tiotropium Bromide,Olodaterol Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Stiolto Respimat
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Tavulus® is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tavulus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
Lannett Company has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler® (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lannett Company, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 29, 2021
Details:
Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name. Tiogiva® in UK Tiogiva® is the bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler®. Tiotropium Bromide DPI is used in the treatment of COPD.
Lead Product(s): Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tiogiva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
Subgroup analysis of Phase 2b data will be provided by Verona Pharma showing that nebulized ensifentrin as monotherapy or applied to tiotropium enhances lung function in moderate to serious COPD patients regardless of smoking status or chronic bronchitis history over 4 weeks.
Lead Product(s): Ensifentrine,Tiotropium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
